Home
Clinical Trials
Immediate Versus Substantiate...

Immediate Versus Substantiated Antibiotic Therapy in Suspected Non-Severe Ventilator-Associated Pneumonia

Last Updated: 2025-12-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

Total Enrollment

686 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-11

Study Completion Date

2029-02-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Ventilator-associated pneumonia is the leading nosocomial infection in the intensive care units, and is associated with prolonged mechanical ventilation and overuse of antibiotics. Initiating antibiotic therapy immediately after bacteriological sampling (immediate strategy) may expose uninfected patients to unnecessary treatment, while waiting for bacteriological confirmation (conservative strategy) may delay ventilator-associated pneumonia in infected patients.

The decision to start antibiotic therapy for ventilator-associated pneumonia takes three points into account: diagnostic probability, the risks to the patient if Antibiotic Therapy is delayed, and the risk of selection of resistant bacteria. Diagnostic probability is limited, given the subjective and non-specific nature of the diagnostic criteria, and only 30-50% of suspected cases are confirmed bacteriologically (whereas samples are only taken when the pre-test probability is sufficient). The risks associated with delayed antibiotic therapy are unknown, as few observational studies have directly assessed the impact of the timing of Antibiotic Therapy initiation on outcome (frequent confusion between delayed and inappropriate Antibiotic Therapy).

Iregui et al. found that delaying Antibiotic Therapy by more than 24 hours was associated with higher mortality. However, more recent before-and-after studies have shown that the conservative strategy was associated with lower mortality, more frequently appropriate initial Antibiotic Therapy and shorter duration of Antibiotic Therapy. Similarly, in a recent before-and-after study by our team, initiating antibiotic therapy only upon microbiological confirmation of ventilator-associated pneumonia without septic shock or severe acute respiratory distress syndrome was not associated with an increase in ventilation time, length of stay or excess mortality at D28; but was associated with antibiotic therapy that was more often appropriate (DELAVAP, MARTIN et al, Annals of Intensive Care, 2024). Finally, the recent multicenter TARPP pilot study in surgical intensive care suggests that antibiotic therapy initiated on the basis of microbiological data in patients with suspected ventilator-associated pneumonia not requiring vasopressor support is not associated with a poorer outcome than immediate antibiotic therapy without documentation (the only randomized study on this subject).

Antibiotic Therapy for suspected ventilator-associated pneumonia that is not subsequently confirmed is an unnecessary use of antibiotics and carries a risk of selection of resistant bacteria, with adverse effects on public health. It has been reported that a conservative Antibiotic Therapy prescription strategy for intensive care units -acquired infections reduces Antibiotic Therapy use and the incidence of acquired β-lactamase-producing Enterobacteriaceae infections.

Overall, in patients with suspected ventilator-associated pneumonia but no signs of clinical severity, given the uncertainty about attributable mortality and concerns about bacterial resistance, the evaluation of the conservative Antibiotic Therapy strategy is reasonable. Some French intensive care units already delay Antibiotic Therapy until confirmation of ventilator-associated pneumonia, except in patients with severe hypoxemia or the need for vasopressor support.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Delayed Antibiotic Therapy in Non-severe Ventilator Acquired Pneumonia (VAP)

NCT05205525

Ventilator Associated Pneumonia Critical Care Antibiotic Therapy

COMPLETED

Empiric Antibiotic Therapy for Ventilator-acquired Pneumonia With Gram-negative Bacilli in Intensive Care

NCT02127528

Ventilator-associated Pneumonia

UNKNOWN

Impact of Direct Antimicrobial Susceptibility Testing on Respiratory Sample of Intensive Care Patient With Suspected VAP

NCT02897466

Ventilator-associated Pneumonia

UNKNOWN NA

Impact of Antibio Prophylaxis on Occurence of Ventilator Associated Pneumonia in Trauma Patients

NCT07059039

Ventilator Associated Pneumonia ( VAP)

COMPLETED

Defining Antibiotic Treatment Duration for Ventilator - Associated Lung Infection

NCT03382548

Ventilator Associated Pneumonia Pneumonia, Bacterial

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ventilator-Associated Pneumonia (VAP)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Immediate strategy

Usual Care

Group Type ACTIVE_COMPARATOR

control group

Intervention Type PROCEDURE

immediate empiric Antibiotic Therapy (started within 1 hour after randomization) with antibiotic(s) chosen by the bedside physician based on time of ventilator-associated pneumoniaoccurrence, risk of antimicrobial resistance, local ecology, and local protocol. If the respiratory samples are negative, Antibiotic Therapy will be stopped. If ventilator-associated pneumonia is confirmed by positive samples, Antibiotic Therapy active against the recovered bacterial specie(s) will be given for a total of 7 days.

Conservative strategy

Group Type EXPERIMENTAL

Conservative strategy

Intervention Type PROCEDURE

No Antibiotic Therapy until receipt of the respiratory sample culture and/or polymerase chain reaction results. If these results are negative, no Antibiotic Therapy is given. If they are positive (confirmed ventilator-associated pneumonia), Antibiotic Therapy is started as appropriate for the bacterial specie(s) detected by culture and/or polymerase chain reaction, without considering gram-stain results and without waiting for antimicrobial susceptibility testing results, and continued for a total of 7 days of Antibiotic Therapy active against the identified bacterial specie(s).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

control group

Intervention Type PROCEDURE

Conservative strategy

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Invasive mechanical ventilation for longer than 48 hours
* Respiratory sample collection taken less than two hours ago (at physician discretion, according to local protocol) for a first episode of suspected ventilator-associated pneumonia (meeting the following prespecified criteria) :

* new or changing chest X-ray infiltrates
* plus at least two of the following:

* body temperature ≥38.5°C or ≤35.5°C,
* blood leukocyte count \>12 000/µL or \<4000/µL,
* purulent tracheobronchial aspirate.
* Age ≥18 years
* Informed consent from the patient or next of kin to participation in the trial, or emergency procedure if no next of kin is available
* Patients affiliated to a social security system

* Criteria for severe ventilator-associated pneumonia defined as:

* Vasopressor therapy for onset of septic shock around the time of ventilator-associated pneumonia suspicion
* Onset or severe worsening of hypoxemia (PaO2/FiO2\<150 with 60% FiO2 and 10 mm H2O peak expiratory pressure, or patient on veno-venous extracorporeal membrane oxygenation)
* Immunosuppression defined as :

* leukocytes \<1G/L or neutrophils \<0,5 G/L
* within the last 3 months
* hematopoietic stem-cell transplant or organ transplant with chronic immunosuppressant therapy
* HIV infection with CD4\<50/mm3
* chronic corticosteroid use (\>0.5 mg/kg day for at least one month within the last three months).
* Patient already on Antibiotic Therapy of predicted duration ≥4 weeks (endocarditis, spondylodiscitis, abscess...)
* Previous ventilator-associated pneumonia suspicion with sampling and/or Antibiotic Therapy for suspected ventilator-associated pneumonia
* Previous inclusion in the trial
* Patient included in an interventional study on ventilator-associated pneumonia management with the same primary endpoint.
* Pregnancy, recent delivery, or breastfeeding
* Correctional facility inmate, adult under guardianship
* Patient under legal protection
* Life expectancy less than 48 hours and/or decision to withhold and/or withdraw life-sustaining therapies
* Organ donor reanimation

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers